Literature DB >> 2558814

Absence of "A"-esterase activity in the serum of a patient with Tangier disease.

M I Mackness1, E Peuchant, M F Dumon, C H Walker, M Clerc.   

Abstract

The levels of apolipoprotein A-I, A-II and B in subjects who are homozygous or heterozygous for Tangier disease are reported and compared with the amount of "A"-esterase in the serum. The "A"-esterases hydrolyse toxic organophosphate pesticides and are currently classified by the nomenclature committee of the International Union of Biochemistry as arylesterases (EC 3.1.1.2) although recent evidence has cast doubt on this classification. The apolipoprotein data are consistent with previous data reported for a number of Tangier patients. The homozygote has a marked reduction in apo A-I and A-II levels and a 30% reduction in apo B. The heterozygotes have about a 50% reduction of apo A-I, a slight reduction in apo A-II and no change in apo B. These apolipoprotein values correspond to a marked reduction in HDL cholesterol for the homozygote and substantial reductions in the heterozygotes. The "A"-esterase activity is zero in one homozygote while heterozygotes have about 5% of the levels in control subjects. Arylesterase activity appears to be essentially normal. The data thus support previous observations that the HDL "A"-esterase activity is greatly reduced in those conditions where HDL apo A-I is markedly reduced, e.g., in "Fish-eye" Disease.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2558814     DOI: 10.1016/s0009-9120(89)80101-8

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  6 in total

Review 1.  Pharmacogenetics of paraoxonase activity: elucidating the role of high-density lipoprotein in disease.

Authors:  Daniel Seung Kim; Judit Marsillach; Clement E Furlong; Gail P Jarvik
Journal:  Pharmacogenomics       Date:  2013-09       Impact factor: 2.533

2.  Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes.

Authors:  M C Garin; R W James; P Dussoix; H Blanché; P Passa; P Froguel; J Ruiz
Journal:  J Clin Invest       Date:  1997-01-01       Impact factor: 14.808

3.  DNA polymorphisms in two paraoxonase genes (PON1 and PON2) are associated with the risk of coronary heart disease.

Authors:  D K Sanghera; C E Aston; N Saha; M I Kamboh
Journal:  Am J Hum Genet       Date:  1998-01       Impact factor: 11.025

4.  Quantification of human serum paraoxonase by enzyme-linked immunoassay: population differences in protein concentrations.

Authors:  M C Blatter Garin; C Abbott; S Messmer; M Mackness; P Durrington; D Pometta; R W James
Journal:  Biochem J       Date:  1994-12-01       Impact factor: 3.857

5.  Associations between high density lipoprotein mean particle size and serum paraoxonase-1 activity.

Authors:  Amirnader Emami Razavi; Mohsen Ani; Morteza Pourfarzam; Gholam Ali Naderi
Journal:  J Res Med Sci       Date:  2012-11       Impact factor: 1.852

6.  Impacts on Sirtuin Function and Bioavailability of the Dietary Bioactive Compound Dihydrocoumarin.

Authors:  Jennifer L Jacobi; Bo Yang; Xu Li; Anna K Menze; Sara M Laurentz; Elsa M Janle; Mario G Ferruzzi; George P McCabe; Clint Chapple; Ann L Kirchmaier
Journal:  PLoS One       Date:  2016-02-16       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.